Our Science – Ho Website
Mitchell Ho, Ph.D.
| Q&A With Mitchell Ho, Ph.D. - Dr. Ho is a recipient of Ovarian Cancer Research Fund's Individual Investigator Award.|
| The NIH Antibody Interest Group (ABIG) - Monthly ABIG serminar series are open to everyone interested.|
BIOC301/302 - Biochemistry I/II
- FAES Graduae School at the NIH.
BIOC 301 and 302 are a comprehensive survey of biochemistry at the graduate level.
| Understanding Mesothelioma By CURE Media Group - Q&A With Dr. Mitchell Ho, the recipient of the Mesothelioma Applied Research Foundation Craig Kozicki Memorial Grant|
| NCI/CCR: Novel Antibody Targets Glypican-3 in Liver Cancer - The Ho lab generated a new human single-domain antibody, HN3, that recognizes glypican-3 for liver cancer therapy. (NCI/CCR News. March 11, 2013)|
| Nature Reviews: The promise of new approaches in the management of hepatocellular carcinoma - "Mitchell Ho and colleagues investigated the potential of therapeutic antibodies for HCC." Nature Reviews Gastroenterology and Hepatology, Published online 26 March 2013|
| Nature SciBX: Glypican-3 (GPC3) - NCI patent application filed; available for licensing. Contact: Mitchell Ho, National Cancer Institute, Bethesda, MD. e-mail: email@example.com. SciBX 6(11); doi:10.1038/scibx.2013.262 Published online March 21 2013|
Dataset: Global Gene Expression Microarray for 2D and 3D Cultures of NCI-H226
- Gene expression microarray datasets from the NCI-H226 mesothelioma cell line: 2D and 3D cell cultures.
| Dr Mitchell Ho's talk at 2013 AACR Annual Meeting - Immune-based therapies targeting mesothelin and MUC16/CA125 (video and slides)|
| Breast Cancer Startup Challenge - The Challenge is comprised of 10 technologies that were developed in the research labs funded by NCI or Avon Foundation. The antibody technology developed in the Ho lab is one of these 10 inventions.|
| Single-Domain Antibodies and IL12-based Immunocytokines - Interview with Dr. Mitchell Ho, Genetic Engineering & Biotechnology News (Vol.33, No. 16; Sept 15, 2013)|
| Novel Antibody Targets Glypican-3 in Liver Cancer - CCR Connections (Volume 7, No. 1; 2013)|
| NCI's Introduction to Cancer Research Careers (ICRC) Program - Arelys Flores Vazquez, an ICRC Summer Intern in the Ho lab, presented at 2013 NIH Summer Poster Day.|
| NCI/CCR: Wnt Inactivation for Liver Cancer Therapy - The Ho lab demonstrates the development of a human monoclonal antibody targeting the heparan sulfate chains of glypican-3 involved in the Wnt signaling pathway, providing a potential cancer therapy. (NCI/CCR News. January, 2014)|
This page was last updated on 3/20/2014.